Organon and
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Organon and sits in the top decile of US sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count).
Organon and: 15 sponsored US clinical trials, 1 recruiting.
Organon and sponsors 15 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 12 completed. 12 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Atopic Dermatitis, with 4 trials.
Top-decile sponsor footprint
Organon and ranks in the top decile of sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
12 of 13 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (92.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
15 total, page 1 of 1
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
NCT07265479
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
NCT05172726
A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck Region
NCT05789576
A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque Psoriasis
NCT05680740
A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain
NCT05560646
Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive
NCT05264506
Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis
NCT05186805
Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis
NCT05142774
Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102)
NCT05032859
Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults
NCT05014568
A Study to Assess Contraceptive Efficacy and Safety of Etonogestrel (ENG) Implant Beyond 3 Years of Use (MK-8415-060)
NCT04626596
Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)
NCT04053387
Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis
NCT04042103
Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002)
NCT03983980
Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)
NCT03956355
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
| Phase 3 | 10 |
| Phase 4 | 2 |
Therapeutic Areas
Where Organon and enrollment is open (later-stage tilt)
1 recruiting of 15 indexed (7% open); 12 completed (80%).
Phase mix: 12 late (III/IV) vs 3 early (I/II) (later-stage heavy).
Top condition: Atopic Dermatitis (4 trials), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Organon and: open-pipeline peers nationwide
Peers matched on 15 registered trials and 7% open enrollment, not the therapeutic-area sidebar.
Organon and sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 15 trials (± recruiting share)
- Allakos · 15 trials · 0% recruiting
- Arbor Research Collaborative for Health · 15 trials · 33% recruiting
- Arena Pharmaceuticals · 15 trials · 0% recruiting
- Arrowhead Pharmaceuticals · 15 trials · 20% recruiting
Sponsors near 7% open enrollment (± trial volume)
- Baylor Breast Care Center · 7% recruiting · 15 trials
- Geron Corporation · 7% recruiting · 15 trials
- Guerbet · 7% recruiting · 15 trials
- Joanne Kurtzberg, MD · 7% recruiting · 15 trials
Related
What to do with this Organon and page
15 registered trials is a research-attention snapshot, not an endorsement of Organon and or any single study.
- 1 of Organon and's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Atopic Dermatitis is the condition Organon and studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Atopic Dermatitis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Organon and pipeline card: 15 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.